A recent Cardiology digest,
as sent to subscribers

Study Type: Pragmatic stepped-wedge cluster-randomised trial (six EDs, 59,980 presentations).

Key Question: Does adding point-of-care hs-cTnI testing to an accelerated diagnostic pathway reduce ED length of stay, without compromising safety, versus central laboratory hs-cTn testing?

Key Findings:

• Adjusted ED length of stay fell by 13% (95% CI 9-16%; P<0.001), equating to 47 minutes (95% CI 33-61) against a control mean of 376 minutes.
• 30-day MI or cardiac death was identical in both arms (0.39% vs 0.39%; P=0.54).
• Whole-blood point-of-care testing was integrated into a single-sample rule-out pathway.

Clinical Relevance: Supports point-of-care hs-cTn as a means of improving ED flow and reducing crowding in NHS departments, though local laboratory turnaround times will influence the benefit.

Limitations: Safety was assessed through 30-day event rates with no formal non-inferiority margin stated in the abstract, and the effect size may not generalise to settings with faster central laboratory turnaround.

Study Type: Functional genomics study (high-throughput deep mutational scanning) with supporting case-control and biobank analyses.

Key Question: Can large-scale functional assays classify KCNQ1 variants of uncertain significance (VUS) and define mechanisms linking variants to long QT syndrome (LQTS) and arrhythmia risk?

Key Findings:

• 13,403 coding variants were tested across 4 assays (49,305 measurements); 1,757 showed strong pathogenic evidence and 6,660 moderate benign evidence.
• Loss-of-function variants were significantly associated with QT prolongation and LQTS in case-control and biobank analyses (effect sizes not given in abstract).
• Most pathogenic variants were dominant-negative, and these carried higher arrhythmia diagnosis risk than haploinsufficient variants. Deleterious variants clustered in distinct structural domains by functional class.

Clinical Relevance: This offers a functional evidence resource that could support reclassification of KCNQ1 VUS in UK inherited cardiac conditions services and help refine arrhythmia risk stratification.

Limitations: Findings derive from in vitro cellular assays, and the abstract does not report validation of reclassified variants against clinical outcomes or effect sizes for the risk associations.

Study Type: Narrative state-of-the-art review (no systematic methodology described in the abstract).

Key Question: What is the current understanding of the pathophysiology, presentation, management and prevention of radiation-associated coronary artery disease (RACAD), and where do evidence gaps remain?

Key Findings:

• Risk is determined by radiotherapy factors (cardiac dose, proximity of coronaries to the field) and patient factors (younger age, higher baseline cardiovascular risk, concurrent cardiotoxic systemic therapy).
• Presentation is early (1–2 years) after high cardiac doses (e.g. lung, oesophageal cancer) or delayed (5–20 years) after lower doses (e.g. left-sided breast cancer); symptoms mimic conventional CAD but may be under-recognised in cancer survivors.
• Management follows standard CAD guidelines, adapted for oncological surgery, bleeding risk and post-radiotherapy complications such as atretic internal mammary arteries.

Clinical Relevance: Cardiology teams in the UK should maintain a low threshold for ischaemia assessment in prior thoracic radiotherapy patients, and contribute to cardio-oncology multidisciplinary planning given growing numbers of survivors.

Limitations: As a narrative review, it provides no quantitative effect estimates, and the authors acknowledge major gaps, including the lack of validated dosimetry-based risk models, surveillance protocols, and evidence comparing percutaneous with surgical revascularisation.

Study Type: Scientific statement (expert consensus document); not original research and no systematic evidence synthesis described.

Key Question: How do the surgeon, anaesthetist and perfusionist each approach intraoperative management in aortic surgery, and where do their actions affect one another?

Key Findings:

• No quantitative data, effect sizes or graded recommendations are reported in the abstract.
• The statement presents three professional perspectives (surgeon, anaesthesiologist, perfusionist), emphasising that one team member's actions have immediate consequences for the others.
• Aortic-specific complexities highlighted include single-lung ventilation, systemic cooling and rewarming, and myocardial, cerebral and visceral protection.

Clinical Relevance: Aortic centres in the UK (including aortic teams and surgical MDTs) may find it useful as a framework for intraoperative communication and team briefing, though it reflects US practice and professional structures.

Limitations: The authors state it is deliberately non-exhaustive, so it offers illustrative concerns rather than evidence-graded, actionable recommendations.

Study Type: Cross-sectional observational cohort study (single-country, case-control comparison).

Key Question: Does lifelong LDL-cholesterol exposure in heterozygous familial hypercholesterolaemia (FH) impair thymic output, and is this modified by lipid-lowering therapy?

Key Findings:

• Treatment-naïve FH patients (n=236) had reduced CD4+ recent thymic emigrants versus healthy controls (n=295), most marked in those aged 18–30 or with highly pathogenic *LDLR* variants; TREC analysis showed reduced output in naïve CD4+ and CD8+ cells.
• FH patients reached the control median CD4+ RTE percentage ~6 years earlier (approx. 19 vs 25.5 years), with TCR-β sequencing showing skewing towards high-frequency clones.
• Statin-treated FH patients (n=326), especially females, had higher CD4+ RTE levels than statin-naïve patients.

Clinical Relevance: Suggests FH may carry immunological consequences beyond atherosclerosis, which could strengthen the case for early diagnosis and treatment in UK FH pathways, though clinical implications remain unproven.

Limitations: Cross-sectional, non-randomised design cannot establish causality or a true statin treatment effect (confounding by indication), and findings in a Chinese cohort may not generalise; no clinical immune outcomes were reported.

Study Type: Consensus document (expert review; no original data or systematic methodology described in the abstract)

Key Question: What is the current evidence and recommended practice for diagnosing, treating and determining disposition of acute heart failure (AHF) in prehospital and emergency department settings?

Key Findings:

• Recommends early phenotypic classification (acute decompensated HF, acute pulmonary oedema, isolated RV failure, cardiogenic shock) to guide initial management and triage.
• Reviews evidence on biomarkers, imaging, ventilatory support, diuretics, vasodilators, and early initiation or continuation of guideline-directed medical therapy.
• Supports validated risk stratification tools for disposition decisions; identifies research gaps in prehospital interventions, biomarker-guided therapy, and early disease-modifying treatment.

Clinical Relevance: Offers a framework that could inform ED pathways and ambulance service protocols for AHF in the NHS, though recommendations will need mapping to NICE guidance and local services.

Limitations: The abstract does not state the evidence-grading method or strength of individual recommendations, so their evidential basis cannot be judged without the full text.

Study Type: Secondary analysis of Global Burden of Disease 2023 data (population-level descriptive epidemiology, 55 ESC member countries, 1990-2023).

Key Question: How do CVD burden, risk factor exposure and disease composition differ by sex across the ESC region?

Key Findings:

• Overall burden was similar by sex (women: 55% of cases, 6.0 million; 50% of deaths, 1.5 million), but composition differed: ischaemic heart disease accounted for 21% of CVD in women vs 38% in men; peripheral arterial disease for 23% vs 19%.
• Tobacco and alcohol exposure was 10-20 percentage points higher in men; high BMI and low physical activity were 5-15 points higher in women. Differences in glucose, cholesterol and air pollution were modest.
• Maternal hypertensive disorders comprised 25% of incident CVD in women, with up to 18-fold between-country variation. Cross-country disparity was greater in women (about 3-fold in incidence; up to 25-fold in premature mortality) than in men (about 2-fold in incidence).

Clinical Relevance: Supports sex-informed, life-course prevention in UK practice, including recognising pregnancy-related hypertension as a major contributor to female CVD burden.

Limitations: Modelled GBD estimates depend on variable data quality across countries, and the abstract does not report uncertainty intervals.

Study Type: Cross-sectional, single-centre, laboratory-based physiological study (n=58)

Key Question: Is regular daily nicotine vape use associated with impaired vascular function and cardiorespiratory fitness in young adults without cardiovascular risk factors?

Key Findings:

• FMD was lower in vape users (5.5%) and cigarette smokers (4.4%) than in naive controls (8.3%); CAR was similarly reduced (0.6% and -1.4% vs 4.7%). Vape and cigarette groups appeared broadly comparable.
• Peak VO₂ was lower in vape users than in naive controls but not significantly different between smokers and controls; minute ventilation and cardiac output were lower in both nicotine groups.
• Spirometry and physical activity did not differ across groups. Between-group P values and confidence intervals are not reported in the abstract.

Clinical Relevance: Suggests vaping may cause early endothelial dysfunction and reduced fitness in otherwise low-risk young people, which is pertinent to UK smoking-cessation advice that positions vapes as a lower-harm alternative.

Limitations: Small, cross-sectional design (17 vape users) precludes causal inference and leaves residual confounding possible.